Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 823.02M |
| Revenue (ttm) | 1.64B |
| Net Income (ttm) | -516.47M |
| Shares Out | 77.94M |
| EPS (ttm) | -6.74 |
| PE Ratio | n/a |
| Forward PE | 4.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 961,333 |
| Open | 10.02 |
| Previous Close | 10.43 |
| Day's Range | 9.96 - 10.66 |
| 52-Week Range | 9.96 - 24.37 |
| Beta | 1.02 |
| Analysts | Hold |
| Price Target | 14.83 (+40.44%) |
| Earnings Date | Feb 26, 2026 |
About IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after... [Read more]
Financial Performance
In 2025, IART's revenue was $1.64 billion, an increase of 1.53% compared to the previous year's $1.61 billion. Losses were -$516.47 million, 7337.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for IART stock is "Hold." The 12-month stock price target is $14.83, which is an increase of 40.44% from the latest price.
News
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 20...
Integra LifeSciences Announces Key Executive Leadership Appointments
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Ela...
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025...
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid S...
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearanc...
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation ( IART) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - Presid...
Integra LifeSciences Reports Third Quarter 2025 Financial Results
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third...
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial resu...
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting
Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president an...
Integra LifeSciences Still Recovering From Self-Inflicted Wounds
Integra LifeSciences remains deeply discounted due to ongoing operational setbacks, with the market adopting a cautious 'show me' stance until clear improvements emerge. Remediation and margin improve...
Integra LifeSciences Holdings Corporation (IART) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Mojdeh Poul - President, CEO & Dire...
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Christopher Ward – Senior Director of Investor Relations Lea Daniels Knigh...
Integra LifeSciences Reports Second Quarter 2025 Financial Results
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the secon...
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial res...
Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first pa...
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Integra LifeSciences Holdings Corp. and Encourages Long-Term Investors to Contact the Firm – IART
PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Integra LifeSciences Holdings Corp. (NASDAQ:...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Integra LifeSciences Holdings Corporation (IART) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation ("Integra...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Integra LifeSciences Holdings Corporation (IART) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation ("Integra...